Les Laboratoires Servier SAS - Company Profile
Powered by 
All the sales intelligence you need on Les Laboratoires Servier SAS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Les Laboratoires Servier SAS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Les Laboratoires Servier SAS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Les Laboratoires Servier SAS (Servier) is advancing therapeutic solutions in oncology, cardio-metabolism, venous diseases, and neurology, with a focus on areas where treatment options are limited, such as digestive cancers, gliomas, and hematological cancers. The company offers a wide range of medicines in cardiometabolism, including Atorduo, Coversyl, and Daflon; in oncology, such as Asparlas, Lonsurf, and Onivyde; and in neurology, including Arcalion, Stablon, and Valdoxan. Its research and development efforts focus on immuno-oncology, targeted therapies, and neurological treatments using antisense oligonucleotides and small molecules. The company operates through production sites and research centers in Boston, Denmark, and Paris-Saclay. Servier is headquartered in Suresnes, France.
Headquarters
France
Address
50 Rue Carnot, Suresnes, 92284
Website
www.servier.com
Telephone
33 155 726000
No of Employees
20,000
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$7.4B
Les Laboratoires Servier SAS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapy Areas: | Atorduo |
| Oncology | Carivalan |
| Neurology | Cosyrel |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired the muscular dystrophy business of Edgewise Therapeutics for US$2.65 billion. |
| 2026 | Acquisitions/Mergers/Takeovers | In April, the company acquired Day One Biopharmaceuticals Inc, a biopharmaceutical company. |
| 2026 | Divestiture | In January, the company sold Biogaran to BC Partners, an alternative investment firm. |
Competitor Comparison
| Key Parameters | Les Laboratoires Servier SAS | Pfizer Inc | AstraZeneca Plc | Sanofi | Ipsen SA |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United Kingdom | France | France |
| City | Suresnes | New York City | Cambridge | Paris | Paris |
| State/Province | - | New York | Cambridgeshire | Ile-de-France | Ile-de-France |
| No. of Employees | 20,000 | 75,000 | 96,100 | 76,493 | 5,535 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Olivier Laureau | Chief Executive Officer; President | Senior Management | 2014 | - |
| Dr. Claude Bertrand | Executive Vice President - Research and Development; Chief Scientific Officer | Senior Management | 2018 | - |
| Matthias Staehelin | Chairman | Executive Board | 2022 | - |
| Damien Catoir | General Counsel; Executive Vice President; Secretary | Senior Management | 2023 | - |
| Charlotte Marmousez-Tartar | Executive Vice President - Corporate Strategy & Transformation | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer